Therapeutic Apheresis Services
Providing life-saving and life-enhancing services to adults and children
Our services are delivered across England and North Wales from eight therapeutic apheresis units which operate an outpatient model for non-acute patients. To make a patient referral or discuss services please contact your TAS unit. Patients are either treated in an NHS Blood and Transplant unit or, when clinically appropriate, hospital.
Lilian Hook, Director of Cell Apheresis and Gene Therapies, is supported by a Senior Management Team of Dr James Griffin, Clinical Director; Teresa Baines, Head of TAS and Deputy Chief nurse for Clinical Services; Louise Collingwood, Head of Operations; Nicola Newbound, Senior Nurse of Education and Claire Gillson, Head of Service Development.
For more information read our service portfolio.
Services
TAS supports a range of clinical specialties including haematology, oncology, nephrology, neurology and rheumatology. Therapeutic procedures include:
Peripheral Blood Stem Cell Collection (PBSC)
Collection of peripheral blood stem cells from either patients or donors, which are used for transplantation. Transplantation is usually required following high dose chemotherapy which destroys a patient’s bone marrow.
Lymphocyte Collection (DLI)
Collection of lymphocyte white cells from donors who have previously donated bone marrow or peripheral blood stem cells.
Therapeutic Plasma Exchange (TPE)
Removal of disease mediators, excessive/abnormal constituents from plasma or replacement of deficient constituents.
Red Cell Exchange (RCE)
Removal and replacement of a patient’s red blood cells.
Platelet Depletion
Removal of platelets in patients with very high platelet counts due to disease.
White Cell Depletion
Removal of white cells in patients with very high white cell counts due to disease.
Low Density Lipid Removal (LDL)
Removal of LDL cholesterol molecules using filtration technology.
Extracorporeal Photopheresis (ECP)
An integrated two-stage procedure in which white cells are collected, removed then treated with a photo activated drug and exposed to ultraviolet light before being returned to the patient.
TAS
Information on our services